Boris Duchemann

5.2k total citations
76 papers, 1.0k citations indexed

About

Boris Duchemann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Boris Duchemann has authored 76 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 12 papers in Physiology. Recurrent topics in Boris Duchemann's work include Lung Cancer Treatments and Mutations (35 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Lung Cancer Research Studies (19 papers). Boris Duchemann is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Lung Cancer Research Studies (19 papers). Boris Duchemann collaborates with scholars based in France, Spain and United States. Boris Duchemann's co-authors include Kader Chouahnia, Laurent Zelek, Michaël Soussan, Lucas Goldfarb, C. Chouaïd, Benjamin Besse, Jean‐Baptiste Assié, Laura Mezquita, Thierry Landré and Etienne Giroux‐Leprieur and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Boris Duchemann

68 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Boris Duchemann France 19 675 569 149 140 136 76 1.0k
Hiroshi Wakui Japan 15 412 0.6× 345 0.6× 233 1.6× 57 0.4× 39 0.3× 42 816
Kuo-Ting Chang Taiwan 12 328 0.5× 442 0.8× 213 1.4× 71 0.5× 34 0.3× 22 749
Sven Gogov Switzerland 12 351 0.5× 409 0.7× 294 2.0× 64 0.5× 43 0.3× 25 804
Fumihiko Kinoshita Japan 15 305 0.5× 242 0.4× 58 0.4× 74 0.5× 54 0.4× 62 547
Marco Siano Switzerland 15 297 0.4× 153 0.3× 175 1.2× 73 0.5× 51 0.4× 43 639
Vasiliki Michalaki Greece 10 355 0.5× 236 0.4× 170 1.1× 72 0.5× 20 0.1× 37 707
Maria Vadiaka Greece 13 423 0.6× 194 0.3× 140 0.9× 24 0.2× 50 0.4× 37 697
William Nassib William United States 14 339 0.5× 267 0.5× 227 1.5× 91 0.7× 39 0.3× 44 810
Shinsuke Saisho Japan 17 407 0.6× 321 0.6× 93 0.6× 21 0.1× 87 0.6× 47 722
Marcelo V. Negrão United States 15 491 0.7× 449 0.8× 223 1.5× 14 0.1× 61 0.4× 65 769

Countries citing papers authored by Boris Duchemann

Since Specialization
Citations

This map shows the geographic impact of Boris Duchemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Duchemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Duchemann more than expected).

Fields of papers citing papers by Boris Duchemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Duchemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Duchemann. The network helps show where Boris Duchemann may publish in the future.

Co-authorship network of co-authors of Boris Duchemann

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Duchemann. A scholar is included among the top collaborators of Boris Duchemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Duchemann. Boris Duchemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.
2.
Landré, Thierry, Abdoulaye Karaboué, Zachary S. Buchwald, et al.. (2024). Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 9(2). 102220–102220. 32 indexed citations
3.
Garinet, Simon, Audrey Lupo, Thomas Denize, et al.. (2024). Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice. Pathology. 56(5). 702–709. 2 indexed citations
4.
Fallet, Vincent, et al.. (2023). PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors. Respiratory Medicine and Research. 84. 101018–101018. 5 indexed citations
5.
Teixeira, Luís, Véronique Dièras, Bruno Crestani, et al.. (2023). Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugués dans le cancer du sein : avis d’expert. Bulletin du Cancer. 110(9). 937–949. 2 indexed citations
6.
Oliveira, Ana, Thomas Gille, Elena Bargagli, et al.. (2023). Holistic management of patients with progressive pulmonary fibrosis. Breathe. 19(3). 230101–230101. 5 indexed citations
7.
Valeyre, Dominique, Michel Brauner, Jean‐François Bernaudin, et al.. (2023). Differential diagnosis of pulmonary sarcoidosis: a review. Frontiers in Medicine. 10. 1150751–1150751. 12 indexed citations
8.
9.
Naigeon, Marie, et al.. (2022). Adoptive cell therapies in thoracic malignancies. Cancer Immunology Immunotherapy. 71(9). 2077–2098. 8 indexed citations
10.
11.
Leroy, Karen, I. Monnet, Solenn Brosseau, et al.. (2021). EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers. 13(20). 5132–5132. 14 indexed citations
12.
Duchemann, Boris, Jordi Remón, Marie Naigeon, et al.. (2020). Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers. 12(12). 3625–3625. 28 indexed citations
13.
Sesé, Lucile, Florence Jeny, Y. Uzunhan, et al.. (2020). Adult interstitial lung diseases and their epidemiology. La Presse Médicale. 49(2). 104023–104023. 10 indexed citations
14.
Besse, Benjamin, Julien Adam, Nathalie Cozic, et al.. (2020). 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. Annals of Oncology. 31. S794–S795. 74 indexed citations
15.
Mezquita, Laura, Patricia Martín-Romano, Édouard Auclin, et al.. (2019). MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC. Journal of Thoracic Oncology. 14(10). S272–S273. 3 indexed citations
16.
Costantini, Adrien, Jennifer Corny, Vincent Fallet, et al.. (2018). Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. ERJ Open Research. 4(2). 120–2017. 22 indexed citations
17.
Ferrara, Roberto, Caroline Caramella, Matthieu Texier, et al.. (2017). Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Annals of Oncology. 28. v464–v465. 19 indexed citations
18.
Kossaï, Myriam, Boris Duchemann, C. Boutros, et al.. (2015). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 89(3). 306–310. 8 indexed citations
19.
Annesi‐Maesano, I., et al.. (2013). Epidemiology of idiopathic pulmonary fibrosis in Europe--an update.. PubMed. 30 Suppl 1. 6–12. 3 indexed citations
20.
Duchemann, Boris, Isabella Annesi‐Maesano, Mathilde Neuville, et al.. (2013). Prevalence and incidence of interstitial lung diseases (ILDs) in a French multi-ethnic county. European Respiratory Journal. 42(Suppl 57). P3366–P3366. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroshi Wakui Breakdown of academic impact, for papers by Kuo-Ting Chang Breakdown of academic impact, for papers by Sven Gogov Breakdown of academic impact, for papers by Fumihiko Kinoshita Breakdown of academic impact, for papers by Marco Siano Breakdown of academic impact, for papers by Vasiliki Michalaki Breakdown of academic impact, for papers by Maria Vadiaka Breakdown of academic impact, for papers by William Nassib William Breakdown of academic impact, for papers by Shinsuke Saisho Breakdown of academic impact, for papers by Marcelo V. Negrão
Rankless by CCL
2026